Core Viewpoint - Watson Bio (300142.SZ) has announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund in collaboration with several partners, aiming for a target size of 1 billion yuan, with the company contributing 450 million yuan as a limited partner [1] Group 1: Investment Fund Details - The fund's target size is set at 1 billion yuan [1] - Watson Bio will invest 450 million yuan of its own funds as a limited partner [1] - The fund will focus on various investment areas including synthetic biology, life and health, biological agriculture, bioenergy, biomaterials, technology platform enterprises, and high-throughput equipment [1] Group 2: Investment Areas - Investment areas include synthetic biology such as enzyme preparations, amino acids, and probiotics [1] - Life and health investments will cover plant extracts, recombinant collagen, sweeteners, and protein drugs [1] - Biological agriculture will focus on feed protein, micro-ecological preparations, animal vaccines, and biological nitrogen fixation [1] - Bioenergy investments will include bioethanol and biodiesel [1] - Biomaterials will focus on PLA, PHA, and PDO [1] - The fund will also target technology platform enterprises like strain development and AI protein design [1] - High-throughput equipment investments will include microfluidic devices and gene sequencing equipment [1]

Group 1 - Watson Bio announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund in collaboration with several partners [1] - The target scale of the fund is 1 billion yuan, with Watson Bio contributing 450 million yuan as a limited partner [1] - The fund will primarily invest in the synthetic biology manufacturing industry, including sectors such as synthetic biology, health and wellness, bio-agriculture, bio-energy, bio-materials, and technology platform enterprises [1]

Core Viewpoint - Liaoning Chengda Co., Ltd. plans to establish a biopharmaceutical investment fund in collaboration with its subsidiaries to enhance its competitiveness and capitalize on market opportunities in the healthcare sector [7][11][38]. Group 1: Investment Fund Establishment - The company intends to set up a biopharmaceutical industry investment fund with a total scale not exceeding 1 billion yuan, with an initial scale of 502 million yuan [7][11]. - The fund will focus on the life and health sector, particularly in areas such as innovative drugs, vaccines, and medical services [18][38]. - The fund's structure includes contributions from various subsidiaries, with Liaoning Chengda contributing 100 million yuan, representing approximately 19.92% of the initial fund size [8][11]. Group 2: Investment Strategy and Management - The fund will be managed by Chengda Coastal Industry (Dalian) Fund Management Co., Ltd., which is a wholly-owned subsidiary of the company [14][22]. - The investment strategy includes direct investments in high-quality projects and potential collaborations with other professional investors [18][19]. - The fund aims to achieve returns through strategic investments and timely exits from projects [19][20]. Group 3: Subsidiary Establishment - Liaoning Chengda's subsidiary, Chengda Biological Co., Ltd., plans to establish a wholly-owned subsidiary named Chengda Biological Innovation Pharmaceutical Co., Ltd. with a registered capital of 1 billion yuan [42][44]. - The investment will focus on innovative drug research and development, project acquisitions, and building a professional operational system [44][50]. - This move is part of the company's strategy to diversify its business and enhance its resilience against market fluctuations [50][52].

格隆汇1月26日丨辽宁成大(600739.SH)公布，为更好地实施公司医药医疗板块战略规划，提升公司综合 竞争力和整体价值，及时把握市场化的投资机会，公司拟与控股子公司成大生物、全资子公司成大沿海 及控股子公司深圳成大生物共同投资设立成大生物医药产业投资基金（有限合伙）（暂定名，以最终市 场监督管理机关登记的名称为准）。 基金总规模不超过100,000万元，设立时的规模为50,200万元，其中：成大沿海作为基金管理人、普通合 伙人及执行事务合伙人，拟认缴出资100万元，约占基金设立时份额的0.1992%；深圳成大生物作为普 通合伙人及执行事务合伙人，拟认缴出资100万元，约占基金设立时份额的0.1992%；辽宁成大作为有 限合伙人，拟以自有资金认缴出资10,000万元，约占基金设立时份额的19.9203%；成大生物作为有限合 伙人，拟以自有资金认缴出资40,000万元，约占基金设立时份额的79.6813%。 该基金投资期内各投资人将根据基金投资要求进行实缴。后续将由普通合伙人在基金合伙协议签署之日 起3年内向初始有限合伙人或新的认缴人继续募集直至基金的总认缴出资额达到100,000万元。该基金在 产业投资领域 ...